- Home
- UDMY vs ADPT Comparison
UDMY vs ADPT Comparison
Compare UDMY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- ADPT
- Stock Information
- Founded
- UDMY 2009
- ADPT 2009
- Country
- UDMY United States
- ADPT United States
- Employees
- UDMY N/A
- ADPT N/A
- Industry
- UDMY Other Consumer Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UDMY Real Estate
- ADPT Health Care
- Exchange
- UDMY Nasdaq
- ADPT Nasdaq
- Market Cap
- UDMY 904.2M
- ADPT 1.4B
- IPO Year
- UDMY 2021
- ADPT 2019
- Fundamental
- Price
- UDMY $7.32
- ADPT $9.52
- Analyst Decision
- UDMY Buy
- ADPT Buy
- Analyst Count
- UDMY 11
- ADPT 6
- Target Price
- UDMY $9.90
- ADPT $9.83
- AVG Volume (30 Days)
- UDMY 866.7K
- ADPT 2.5M
- Earning Date
- UDMY 07-30-2025
- ADPT 05-01-2025
- Dividend Yield
- UDMY N/A
- ADPT N/A
- EPS Growth
- UDMY N/A
- ADPT N/A
- EPS
- UDMY N/A
- ADPT N/A
- Revenue
- UDMY $790,019,000.00
- ADPT $189,527,000.00
- Revenue This Year
- UDMY $1.87
- ADPT $25.00
- Revenue Next Year
- UDMY $4.15
- ADPT $20.38
- P/E Ratio
- UDMY N/A
- ADPT N/A
- Revenue Growth
- UDMY 5.43
- ADPT 8.61
- 52 Week Low
- UDMY $5.68
- ADPT $2.99
- 52 Week High
- UDMY $10.61
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- UDMY 58.35
- ADPT 60.15
- Support Level
- UDMY $6.70
- ADPT $8.50
- Resistance Level
- UDMY $7.50
- ADPT $9.69
- Average True Range (ATR)
- UDMY 0.25
- ADPT 0.44
- MACD
- UDMY 0.07
- ADPT -0.01
- Stochastic Oscillator
- UDMY 77.50
- ADPT 77.86
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).